Muscle Relaxation in Myopathies With Positive Muscle Phenomena

Muscle Relaxation Properties in Myopathies With Positive Muscle Phenomena: a Study Using Transcranial Magnetic Stimulation

The aim of this study is to quantify muscle relaxation properties of the finger flexor muscles in patients with different myopathies. The inhibiting effects of transcranial magnetic stimulation (TMS) on the cortical motor hand area are used to induce relaxation, which in turn will be monitored with handgrip dynamometry and EMG. The investigators will evaluate if this technique can be implemented as a diagnostic tool in clinical practice.

Muscle relaxation is an often overlooked property of the muscle as compared to muscle strength or activation. Muscle relaxation is affected in different myopathies, such as myotonic dystrophy, non-dystrophic myotonias, and Brody myopathy. Therefore, a diagnostic tool to quantify muscle relaxation is of clinical and scientific importance. In this study, transcranial magnetic stimulation (TMS) is used, in combination with a dynamometer to quantify muscle relaxation properties.

Transcranial magnetic stimulation (TMS) is a non-invasive technique that is commonly used to stimulate the brain. In practice, a circular coil is held directly above the scalp, upon which a strong current pulse induces a magnetic field that stimulates the underlying superficial brain areas. This stimulation can have both activating and inhibiting effects.

When the motor cortex (i.e. the area of the brain that controls muscle contractions) is strongly stimulated with TMS during a voluntary muscle contraction, both excitatory and inhibitory effects can be observed in the muscle the targeted cortical area controls. The inhibitory effect entails a transient interruption of neural drive to the muscle. This interruption, called the "silent period", lasts for less than half a second and results in the relaxation of the muscle. Muscle activity and control quickly return to normal after the silent period.

The elegance and main advantage of TMS-induced muscle relaxation lies in the fact that it excludes all voluntary influences on the relaxation process. Furthermore, the TMS pulse causes all muscle fibres involved in the contraction just prior to the onset of the silent period to relax simultaneously. This allows us to study muscle relaxation as only a property of the muscle, i.e. without voluntary influences.

In this study, the investigators will measure muscle relaxation in several myopathies (McArdle disease, Nemaline myopathy type 6 and myotonic dystrophy type 2) and compare this to healthy controls and to controls with no myopathy but with similar complaints (myalgia, stiffness, cramps). The data from these two control groups has been gathered previously in a different study. The investigators will also compare this to patients suffering from Brody disease who were previously measured in a different study.

Muscle relaxation will be evaluated in fresh and fatigued finger flexor muscles. The main outcome of this study is the peak relaxation rate normalized to the peak force preceding relaxation.

The final outlook of this research is to evaluate whether muscle relaxation studied with TMS, can be used for different myopathies as a diagnostic tool, to monitor disease progression, and to study the effects of different interventions (e.g. medication, exercise).

Study Overview

• Status: Unknown
• Conditions: Myotonic Dystrophy Type 2; McArdle Disease; Nemaline Myopathy Type 6
• Intervention / Treatment: Diagnostic test: Transcranial magnetic stimulation (TMS)

• Study Type: Observational
• Enrollment (Anticipated): 30

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Diagnosis of one of the following myopathies: Nemaline myopathy type 6 (NEM6), Myotonic dystrophy type 2 (DM2), McArdle disease.

Patients will be selected from a local database at the Radboud University Medical Center. The goal is to include 5 men and 5 women per myopathy.

Description

Inclusion Criteria:

- Diagnosis of one of the following myopathies: Nemaline myopathy type 6 (NEM6), Myotonic dystrophy type 2 (DM2), McArdle disease.

Exclusion Criteria:

• Pregnancy
• Serious head trauma or brain surgery
• Large or ferromagnetic metal parts in the head
• Implanted cardiac pacemaker or neurostimulator
• Epilepsy, convulsion or seizure
• Use of medication that can influence muscle relaxation or cortical excitability

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Nemaline myopathy type 6 (NEM6); Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.	Diagnostic test: Transcranial magnetic stimulation (TMS); Single pulse, monophasic transcranial magnetic stimulation
Myotonic dystrophy type 2 (DM2); Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.	Diagnostic test: Transcranial magnetic stimulation (TMS); Single pulse, monophasic transcranial magnetic stimulation
McArdle disease (McA); Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.	Diagnostic test: Transcranial magnetic stimulation (TMS); Single pulse, monophasic transcranial magnetic stimulation
Healthy controls; 14 male and 10 female healthy subjects were measured in a previous study
Controls with positive muscle phenomena; 9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
Brody disease; 4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Normalized peak relaxation rate	Maximal rate at which the muscle relaxes after the TMS pulse, defined as the steepest point on the force curve. This value is normalised to the force that preceded relaxation, i.e. top of the superimposed twitch.	1 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Force decline at 150ms	The force decline (percentage of peak force) at 150ms after TMS stimulation.	1 hour
Relaxation times (RT)	The time needed for force to decline to a certain percentage of peak force. E.g. the 75% relaxation time, is defined as the time needed for force to decline from 100% (i.e. force before relaxation onset) to 75%. Different relaxation times will be evaluated, e.g. 90% RT, 75% RT, and 50% RT	1 hour
Maximal muscle strength	The highest point on the force curve prior to TMS stimulus	1 hour

Collaborators and Investigators

• Sponsor: Radboud University Medical Center
• Investigators: Principal Investigator: Baziel G van Engelen, MD, PhD, Radboud University Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): January 5, 2017
• Primary Completion (Anticipated): December 31, 2019
• Study Completion (Anticipated): December 31, 2019

Study Registration Dates

• First Submitted: June 28, 2017
• First Submitted That Met QC Criteria: July 6, 2017
• First Posted (Actual): July 7, 2017

Study Record Updates

• Last Update Posted (Actual): October 1, 2019
• Last Update Submitted That Met QC Criteria: September 30, 2019
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Keywords: muscle relaxation; transcranial magnetic stimulation; myopathy
• Additional Relevant MeSH Terms: Metabolic Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Musculoskeletal Diseases; Neuromuscular Diseases; Neurodegenerative Diseases; Muscular Disorders, Atrophic; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Heredodegenerative Disorders, Nervous System; Muscular Dystrophies; Myotonic Disorders; Glycogen Storage Disease; Myopathies, Structural, Congenital; Muscular Diseases; Myotonic Dystrophy; Glycogen Storage Disease Type V; Myopathies, Nemaline
• Other Study ID Numbers: NL57301.091.16

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No